Acerand Therapeutics (Hong Kong) Limited
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Acerand Therapeutics (Hong Kong) Limited sits in the upper half of US sponsors by registered trial count (#7,388 of 15,742 sponsors by registered trial count).
Acerand Therapeutics (Hong Kong) Limited: 1 sponsored US clinical trial, 1 recruiting.
Acerand Therapeutics (Hong Kong) Limited sponsors 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is mCRPC (Metastatic Castration-resistant Prostate Cancer), with 1 trials.
Mid-pack sponsor footprint
Acerand Therapeutics (Hong Kong) Limited is in the upper half of sponsors by trial count (#7,388 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.
Open and recent trials
1 total, page 1 of 1
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
Therapeutic Areas
What is open in the Acerand Therapeutics (Hong Kong) Limited pipeline
1 recruiting of 1 indexed (100% open).
Phase mix: 0 late (III/IV) vs 1 early (I/II) (early-phase heavy).
Top condition: mCRPC (Metastatic Castration-resistant Prostate Cancer) (1 trial), 1 other listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Acerand Therapeutics (Hong Kong) Limited: open-pipeline peers nationwide
Peers matched on 1 registered trials and 100% open enrollment, not the therapeutic-area sidebar.
Acerand Therapeutics (Hong Kong) Limited sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1 trials (± recruiting share)
- 1200 Pharma · 2 trials · 50% recruiting
- 1ST Biotherapeutics · 2 trials · 50% recruiting
- 3 Waves Wellness · 2 trials · 0% recruiting
- 3EO Health · 2 trials · 0% recruiting
Sponsors near 100% open enrollment (± trial volume)
- AAVantgarde Bio Srl · 100% recruiting · 2 trials
- Acorn Biolabs · 100% recruiting · 3 trials
- Acrivon Therapeutics · 100% recruiting · 2 trials
- ADARx Pharmaceuticals · 100% recruiting · 4 trials
Related
What to do with this Acerand Therapeutics (Hong Kong) Limited page
1 registered trials is a research-attention snapshot, not an endorsement of Acerand Therapeutics (Hong Kong) Limited or any single study.
- 1 of Acerand Therapeutics (Hong Kong) Limited's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- mCRPC (Metastatic Castration-resistant Prostate Cancer) is the condition Acerand Therapeutics (Hong Kong) Limited studies most, compare against other sponsors active in the same condition before evaluating a specific study. See mCRPC (Metastatic Castration-resistant Prostate Cancer) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Acerand Therapeutics (Hong Kong) Limited pipeline card: 1 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.